Nos actualités et évènements

Friday, July 19th 2019 at 12:30pm UTC FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize […]

Friday, July 19th 2019 at 7:25pm UTC Brazil’s largest medical education group seeks to transform medical education NEW YORK–(BUSINESS WIRE)– Today, Afya Educacional (“Afya” or “the Company”), Brazil’s largest medical education group,1 lists on the Nasdaq under the ticker symbol NASDAQ:AFYA. The initial public offering of 13,744,210 Class A common shares is priced at $19.00 […]

Friday, July 19th 2019 at 3:37pm UTC DENVER–(BUSINESS WIRE)– The costs and timelines to conduct clinical trials continue to increase, as does study complexity. While much of the focus in clinical trials has been on improving data quality and overall study efficiency addressing cost/timeline/complexity issues, less attention has been paid to the impact of patient […]

Monday, July 22nd 2019 at 6:00am UTC NEUCHATEL, Switzerland–(BUSINESS WIRE)– Masimo (NASDAQ: MASI) announced today that in a study recently published in Anesthesia & Analgesia, researchers evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to detect the development of acute hemodilution after graded fluid administration, by comparing it to invasively measured […]

Friday, July 19th 2019 at 8:08pm UTC WILLIAMSVILLE, N.Y.–(BUSINESS WIRE)– 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a world leader in tobacco harm reduction, announced today that the U.S. Food and Drug Administration (FDA) accepted and filed for substantive scientific review the Company’s Modified Risk Tobacco Product (MRTP) application […]

Friday, July 19th 2019 at 2:30pm UTC LONDON–(BUSINESS WIRE)– High incidence of chronic diseases globally and the need for personalized medicine, has encouraged several technological advancements in the form of recombinant DNA that involves genetic combinations of species to treat diseases. The recombinant DNA technology increases the demand for molecular biology enzymes, kits, and reagents […]

Monday, July 22nd 2019 at 5:00am UTC Vedolizumab subcutaneous is currently under review for approval for ulcerative colitis with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) OSAKA, Japan–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the VISIBLE 2 clinical trial evaluating the efficacy and safety […]

Friday, July 19th 2019 at 1:39pm UTC LONDON–(BUSINESS WIRE)– Several government bodies across the world are enforcing stringent regulations to tackle the adverse environmental effects of mercury emission. Mercury analyzers help in measuring furnace temperature and the flue gas of air pollutants. Thus, the enforcement of strict regulations to monitor environmental pollution is expected to […]

Friday, July 19th 2019 at 8:01pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 7,475,000 shares of its common stock, including 975,000 shares of its common stock pursuant to the underwriters’ exercise in full […]

Monday, July 22nd 2019 at 6:10am UTC Milciclib was well tolerated and no drug related deaths were reported 28 out of 31 treated patients were evaluable, with 14 patients completing the 6-month study duration 9 patients continued treatment under compassionate use, of which 5 are currently continuing with treatment   NEW YORK & LONDON–(BUSINESS WIRE)– […]